- Home
- SNT vs COEP Comparison
SNT vs COEP Comparison
Compare SNT & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- COEP
- Stock Information
- Founded
- SNT 1965
- COEP 2017
- Country
- SNT Canada
- COEP United States
- Employees
- SNT N/A
- COEP N/A
- Industry
- SNT Telecommunications Equipment
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNT Telecommunications
- COEP Health Care
- Exchange
- SNT Nasdaq
- COEP Nasdaq
- Market Cap
- SNT 95.2M
- COEP 86.0M
- IPO Year
- SNT 1993
- COEP N/A
- Fundamental
- Price
- SNT $4.93
- COEP $15.04
- Analyst Decision
- SNT
- COEP
- Analyst Count
- SNT 0
- COEP 0
- Target Price
- SNT N/A
- COEP N/A
- AVG Volume (30 Days)
- SNT 64.1K
- COEP 43.1K
- Earning Date
- SNT 11-11-2025
- COEP 11-12-2025
- Dividend Yield
- SNT N/A
- COEP N/A
- EPS Growth
- SNT N/A
- COEP N/A
- EPS
- SNT 0.22
- COEP N/A
- Revenue
- SNT $38,038,000.00
- COEP $263,555.00
- Revenue This Year
- SNT N/A
- COEP N/A
- Revenue Next Year
- SNT N/A
- COEP N/A
- P/E Ratio
- SNT $22.09
- COEP N/A
- Revenue Growth
- SNT 12.79
- COEP N/A
- 52 Week Low
- SNT $1.40
- COEP $2.31
- 52 Week High
- SNT $5.34
- COEP $19.19
- Technical
- Relative Strength Index (RSI)
- SNT 56.41
- COEP 48.60
- Support Level
- SNT $4.33
- COEP $14.76
- Resistance Level
- SNT $5.34
- COEP $16.45
- Average True Range (ATR)
- SNT 0.32
- COEP 0.84
- MACD
- SNT 0.03
- COEP -0.22
- Stochastic Oscillator
- SNT 62.85
- COEP 18.67
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.